Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.04
BSX's Cash-to-Debt is ranked lower than
96% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. BSX: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
BSX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.13 Max: 0.69
Current: 0.04
0.03
0.69
Equity-to-Asset 0.37
BSX's Equity-to-Asset is ranked lower than
79% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. BSX: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
BSX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.49 Max: 0.57
Current: 0.37
0.21
0.57
Interest Coverage 1.91
BSX's Interest Coverage is ranked lower than
93% of the 241 Companies
in the Global Medical Devices industry.

( Industry Median: 77.33 vs. BSX: 1.91 )
Ranked among companies with meaningful Interest Coverage only.
BSX' s Interest Coverage Range Over the Past 10 Years
Min: 0.37  Med: 1.92 Max: 3.22
Current: 1.91
0.37
3.22
Piotroski F-Score: 7
Altman Z-Score: 0.46
Beneish M-Score: -2.52
WACC vs ROIC
7.50%
5.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 5.33
BSX's Operating Margin % is ranked higher than
59% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. BSX: 5.33 )
Ranked among companies with meaningful Operating Margin % only.
BSX' s Operating Margin % Range Over the Past 10 Years
Min: -53.36  Med: -4.23 Max: 11.86
Current: 5.33
-53.36
11.86
Net Margin % 4.14
BSX's Net Margin % is ranked higher than
59% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. BSX: 4.14 )
Ranked among companies with meaningful Net Margin % only.
BSX' s Net Margin % Range Over the Past 10 Years
Min: -56.12  Med: -4.56 Max: 5.79
Current: 4.14
-56.12
5.79
ROE % 5.39
BSX's ROE % is ranked higher than
58% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. BSX: 5.39 )
Ranked among companies with meaningful ROE % only.
BSX' s ROE % Range Over the Past 10 Years
Min: -44.65  Med: -3.5 Max: 5.39
Current: 5.39
-44.65
5.39
ROA % 1.94
BSX's ROA % is ranked higher than
57% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. BSX: 1.94 )
Ranked among companies with meaningful ROA % only.
BSX' s ROA % Range Over the Past 10 Years
Min: -21.16  Med: -1.48 Max: 2.03
Current: 1.94
-21.16
2.03
ROC (Joel Greenblatt) % 22.96
BSX's ROC (Joel Greenblatt) % is ranked higher than
71% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. BSX: 22.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -144.7  Med: -14.88 Max: 32.39
Current: 22.96
-144.7
32.39
3-Year Revenue Growth Rate 4.60
BSX's 3-Year Revenue Growth Rate is ranked higher than
50% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. BSX: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BSX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 2.7 Max: 28.7
Current: 4.6
-10.5
28.7
3-Year EBITDA Growth Rate 14.70
BSX's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. BSX: 14.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BSX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -71.1  Med: 9.05 Max: 271.1
Current: 14.7
-71.1
271.1
GuruFocus has detected 3 Warning Signs with Boston Scientific Corp $BSX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BSX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BSX Guru Trades in Q1 2016

John Paulson 74,000 sh (New)
Steven Cohen 2,665,600 sh (+286.15%)
Diamond Hill Capital 20,339,317 sh (+3.77%)
Pioneer Investments 3,787,109 sh (+3.24%)
PRIMECAP Management 43,354,400 sh (+0.02%)
Eaton Vance Worldwide Health Sciences Fund 3,450,000 sh (unchged)
Alan Fournier Sold Out
Vanguard Health Care Fund 63,222,390 sh (-1.38%)
Mario Gabelli 796,046 sh (-3.13%)
Dodge & Cox 427,430 sh (-5.19%)
Michael Price 1,740,000 sh (-12.12%)
Ray Dalio 36,184 sh (-59.01%)
Jim Simons 618,405 sh (-82.19%)
» More
Q2 2016

BSX Guru Trades in Q2 2016

Paul Tudor Jones 33,994 sh (New)
Jim Simons 4,901,905 sh (+692.67%)
John Paulson 94,000 sh (+27.03%)
Eaton Vance Worldwide Health Sciences Fund 3,880,000 sh (+12.46%)
PRIMECAP Management 42,640,450 sh (-1.65%)
Dodge & Cox 384,930 sh (-9.94%)
Mario Gabelli 687,746 sh (-13.60%)
Vanguard Health Care Fund 53,619,190 sh (-15.19%)
Pioneer Investments 2,962,863 sh (-21.76%)
Steven Cohen 1,915,982 sh (-28.12%)
Michael Price 900,000 sh (-48.28%)
Ray Dalio 9,684 sh (-73.24%)
Diamond Hill Capital 4,863,821 sh (-76.09%)
» More
Q3 2016

BSX Guru Trades in Q3 2016

Ray Dalio 50,900 sh (+425.61%)
John Paulson 410,000 sh (+336.17%)
Dodge & Cox 382,130 sh (-0.73%)
PRIMECAP Management 41,805,050 sh (-1.96%)
Mario Gabelli 673,046 sh (-2.14%)
Vanguard Health Care Fund 46,520,049 sh (-13.24%)
Steven Cohen 1,622,600 sh (-15.31%)
Paul Tudor Jones 26,610 sh (-21.72%)
Michael Price 700,000 sh (-22.22%)
Diamond Hill Capital 3,289,862 sh (-32.36%)
Pioneer Investments 1,878,761 sh (-36.59%)
Jim Simons 1,884,005 sh (-61.57%)
Eaton Vance Worldwide Health Sciences Fund 1,698,025 sh (-56.24%)
» More
Q4 2016

BSX Guru Trades in Q4 2016

Joel Greenblatt 99,384 sh (New)
David Tepper 550,000 sh (New)
Ray Dalio 91,000 sh (+78.78%)
Jim Simons 2,625,305 sh (+39.35%)
Pioneer Investments 1,941,017 sh (+3.31%)
Diamond Hill Capital 3,351,408 sh (+1.87%)
PRIMECAP Management 41,920,457 sh (+0.28%)
Michael Price 700,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Dodge & Cox 371,671 sh (-2.74%)
Mario Gabelli 653,146 sh (-2.96%)
Vanguard Health Care Fund 43,872,669 sh (-5.69%)
John Paulson 288,000 sh (-29.76%)
Steven Cohen 358,400 sh (-77.91%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ISRG, NYSE:ZBH, NYSE:STJ, NYSE:EW, NYSE:SYK, OTCPK:SNNUF, NAS:ALGN, OTCPK:SONVY, NYSE:TFX, NYSE:VAR, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:CNVVY, OTCPK:WILLF, NAS:ABMD, NAS:MASI, OTCPK:FSPKF, NAS:NUVA, OTCPK:EKTAY, OTCPK:GGNDF » details
Traded in other countries:BSX.Germany,
Boston Scientific Inc is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Top Ranked Articles about Boston Scientific Corp

Diamond Hill Buys Ford, Sells Boston Scientific Firm's largest 2nd quarter trades
Diamond Hill Capital (Trades, Portfolio) Management Inc. was established in 2000 and is a registered investment adviser based in Columbus, Ohio. During the second quarter, the firm traded the following stocks. Read more...
Michael Price Trims Boston Scientific, Buys Outerwall The guru's largest trades of 2nd quarter
Michael Price (Trades, Portfolio) is the 271st richest person in the world, according to Forbes. A renowned money manager, he learned finance as a $200-a-week research assistant under Max Heine. The following are his largest trades of the second quarter: Read more...
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Guru exited position in Pfizer in 2nd quarter
Seven of Vanguard Health Care Fund (Trades, Portfolio)’s top 10 second-quarter transactions were divestitures or reductions, including its most noteworthy deal of the quarter. Read more...
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Recent insider sells from company CEOs
According to GuruFocus Insider Data, these are the largest CEO sells during the past week: Gilead Sciences Inc., Boston Scientific Corp., Sonic Corp. and HealthEquity Inc. Read more...

Ratios

vs
industry
vs
history
PE Ratio 95.04
BSX's PE Ratio is ranked lower than
88% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 26.64 vs. BSX: 95.04 )
Ranked among companies with meaningful PE Ratio only.
BSX' s PE Ratio Range Over the Past 10 Years
Min: 13.87  Med: 34.92 Max: 404.33
Current: 95.04
13.87
404.33
Forward PE Ratio 19.76
BSX's Forward PE Ratio is ranked higher than
74% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.98 vs. BSX: 19.76 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 95.04
BSX's PE Ratio without NRI is ranked lower than
89% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. BSX: 95.04 )
Ranked among companies with meaningful PE Ratio without NRI only.
BSX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.87  Med: 34.92 Max: 404.33
Current: 95.04
13.87
404.33
Price-to-Owner-Earnings 51.90
BSX's Price-to-Owner-Earnings is ranked lower than
74% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 30.84 vs. BSX: 51.90 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BSX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.58  Med: 42.5 Max: 936
Current: 51.9
11.58
936
PB Ratio 5.02
BSX's PB Ratio is ranked lower than
68% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. BSX: 5.02 )
Ranked among companies with meaningful PB Ratio only.
BSX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.35 Max: 5.3
Current: 5.02
0.59
5.3
PS Ratio 4.04
BSX's PS Ratio is ranked lower than
57% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. BSX: 4.04 )
Ranked among companies with meaningful PS Ratio only.
BSX' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.2 Max: 4.15
Current: 4.04
1.02
4.15
Price-to-Free-Cash-Flow 56.55
BSX's Price-to-Free-Cash-Flow is ranked lower than
81% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 28.14 vs. BSX: 56.55 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.26  Med: 20.29 Max: 220
Current: 56.55
7.26
220
Price-to-Operating-Cash-Flow 34.76
BSX's Price-to-Operating-Cash-Flow is ranked lower than
72% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. BSX: 34.76 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.79  Med: 15.66 Max: 62.72
Current: 34.76
5.79
62.72
EV-to-EBIT 40.90
BSX's EV-to-EBIT is ranked lower than
95% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 22.27 vs. BSX: 40.90 )
Ranked among companies with meaningful EV-to-EBIT only.
BSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2577.3  Med: -5.65 Max: 25784.2
Current: 40.9
-2577.3
25784.2
EV-to-EBITDA 17.62
BSX's EV-to-EBITDA is ranked lower than
86% of the 238 Companies
in the Global Medical Devices industry.

( Industry Median: 16.71 vs. BSX: 17.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 8.3 Max: 241.8
Current: 17.62
-680.1
241.8
Current Ratio 0.90
BSX's Current Ratio is ranked lower than
88% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. BSX: 0.90 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.37 Max: 1.94
Current: 0.9
0.78
1.94
Quick Ratio 0.64
BSX's Quick Ratio is ranked lower than
87% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. BSX: 0.64 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.09 Max: 1.67
Current: 0.64
0.5
1.67
Days Inventory 149.67
BSX's Days Inventory is ranked lower than
61% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. BSX: 149.67 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 113.61  Med: 133.18 Max: 164.78
Current: 149.67
113.61
164.78
Days Sales Outstanding 64.07
BSX's Days Sales Outstanding is ranked higher than
56% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. BSX: 64.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 64.07
58.51
66.79
Days Payable 67.28
BSX's Days Payable is ranked higher than
55% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. BSX: 67.28 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 35.22 Max: 67.31
Current: 67.28
21.66
67.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. BSX: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.3  Med: -0.7 Max: 4.6
Current: -1
-22.3
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.69
BSX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
64% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. BSX: 2.69 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.47 Max: 4.27
Current: 2.69
0.52
4.27
Price-to-Median-PS-Value 1.84
BSX's Price-to-Median-PS-Value is ranked lower than
83% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. BSX: 1.84 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.32 Max: 4.04
Current: 1.84
0.49
4.04
Price-to-Peter-Lynch-Fair-Value 1.39
BSX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. BSX: 1.39 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BSX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.42 Max: 2.88
Current: 1.39
0
2.88
Earnings Yield (Greenblatt) % 2.44
BSX's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. BSX: 2.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 2.5 Max: 9.1
Current: 2.44
0.5
9.1
Forward Rate of Return (Yacktman) % 42.16
BSX's Forward Rate of Return (Yacktman) % is ranked higher than
97% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 9.85 vs. BSX: 42.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BSX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.1  Med: 6.9 Max: 42.16
Current: 42.16
3.1
42.16

More Statistics

Revenue (TTM) (Mil) $8,386
EPS (TTM) $ 0.26
Beta0.85
Short Percentage of Float1.19%
52-Week Range $17.87 - 25.65
Shares Outstanding (Mil)1,363.49

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,820 9,448 10,070
EPS ($) 1.25 1.43 1.62
EPS without NRI ($) 1.25 1.43 1.62
EPS Growth Rate
(Future 3Y To 5Y Estimate)
22.21%
Dividends per Share ($)
» More Articles for BSX

Headlines

Articles On GuruFocus.com
10 Most Overvalued Stocks of the S&P 500 Mar 06 2017 
GuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare Feb 15 2017 
John Paulson Continues to Buy These 8 Stocks Dec 23 2016 
Medtronic Misses 2nd Quarter Revenue Expectations Nov 27 2016 
Michael Price Sells Dolby Labs, EMC Nov 21 2016 
Vanguard Health Care Fund Sells Amgen, Baxter Nov 02 2016 
Michael Price Trims Boston Scientific, Buys Outerwall Aug 23 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 

More From Other Websites
​Boston Scientific's CEO got $36 million in compensation, stock value last year Mar 29 2017
Boston Scientific Corp. breached its 50 day moving average in a Bullish Manner : BSX-US : March 28,... Mar 28 2017
Medtronic Does Heart-Valve Study, And Rivals Reap The Benefits Mar 17 2017
Boston Scientific Corp. breached its 50 day moving average in a Bearish Manner : BSX-US : March 17,... Mar 17 2017
NICE Recommends Boston Scientific CRT-D Devices Powered By EnduraLife™ Battery Technology For... Mar 16 2017
German Court Rules In Favor Of Boston Scientific Corporation (BSX) In Patent Case Against Edwards... Mar 10 2017
Boston Scientific and Edwards Lifesciences Are in a Patent Battle Mar 10 2017
Blog Coverage German and UK Courts Rule in Favor of Boston Scientifics' Patent Related Litigation... Mar 10 2017
Boston Scientific Wins In Patent Battle Vs. Edwards In German Court Mar 09 2017
Boston Scientific Receives Favorable Rulings In Edwards Lifesciences Litigation Mar 09 2017
Boston Scientific To Participate In Barclays Global Healthcare Conference Mar 07 2017
At ​Boston Scientific, device tax reprieve spurs mostly ex-U.S. job growth Mar 07 2017
Boston Scientific Announces Six Finalists in 2nd Annual Connected Patient Challenge, Focused on... Mar 03 2017
BOSTON SCIENTIFIC CORP Financials Mar 01 2017
Boston Scientific Corporation (BSX) Lotus Transcatheter Recalled After Discovery Of Fault And Death... Feb 24 2017
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Boston Scientific Corporation and... Feb 24 2017
Boston Scientific Recalls Lotus Heart Devices Feb 24 2017
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Boston Scientific Corporation... Feb 24 2017
[$$] Boston Scientific Recalls Lotus Heart Valve Device Feb 23 2017
Asian stocks fall amid Trump trade policy fears, strong yen Feb 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)